Life Science Software Market Revenue to Attain USD 48.97 Bn by 2035

Published: 10 Feb 2026

Author: Precedence Research

Share:

Life Science Software Market Revenue and Trends 2026 to 2035

The global life science software market revenue was valued at USD 17.7 billion in 2025 and is expected to attain around USD 48.97 billion by 2035, growing at a CAGR of 10.68% during forecast period.This market is experiencing unprecedented growth, driven by the rising complexity of clinical trials and rapid technological innovation in the life science sector.

What Drives the Growth of the Life Science Software Market?

The rising adoption of cloud-based solutions, AI/ML integration for drug discovery, and strict regulatory compliance across the biopharmaceutical industry are the major drivers, accelerating the growth of the life science software market during the forecast period. Cloud-based platforms efficiently manage complex, large, and real-time datasets in genomics and proteomics. Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being used to accelerate drug discovery, clinical trials, and patient management. Moreover, the growing demand for precision medicine requires software to analyze genomic data and support targeted therapies are expected to fuel the expansion of the market.

Segment Insights

• By deployment, the on-premise segment registered its dominance in the market, owing to the stringent regulatory compliance and increasing demand for greater customization and the growing need for smooth integration with complex and legacy laboratory systems. On-premises deployments remain critical for pharmaceuticals and biotech organizations, owing to the increasing need for full data and security control to manage sensitive data.
• By application, the preclinical and clinical trials segment contributed the biggest market share in 2025. The segment’s growth is driven by the rising need to manage complex preclinical and clinical trial data, the growing demand to accelerate drug development, and the increasing focus on aligning with strict regulatory compliance. The integration of AI and cloud-based platforms streamlines workflows, enhances data accuracy, and reduces human error in clinical trials.
• By end-user, the biotechnology and pharmaceutical companies segment held the largest market share in 2025. This is because these companies heavily utilize life science software to manage large datasets from clinical trials, genomics, and personalized medicine to accelerate development timelines. The stringent regulatory norms of the regulatory bodies compel the biotechnology and pharmaceutical companies to adopt software for data integrity, traceability, and automated compliance.

Regional Insights

North America holds the dominant share in the global life science software market. The region strongly benefits from the well-established healthcare IT infrastructure, significant R&D investments, and early adoption of AI/ML technologies. The region’s leadership in the market is driven by the presence of leading biotechnology and pharmaceutical companies, growing need for faster data analysis, rapid growth in personalized medicine, escalating demand for AI-based drug discovery, high demand for R&D digitization, and growing demand for AI-driven drug discovery, and strict regulatory compliance. Moreover, the increasing need for digital solutions in streamlining clinical workflows and the rising shift toward cloud-based platforms are anticipated to propel the growth of the market in the region.

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. This rapid expansion is driven by the region’s developing healthcare sector, rising R&D investments, growing demand for targeted therapies, and increasing complexity of clinical trials. Strict regulatory requirements and the adoption of AI, machine learning, and cloud-based software further fuel market growth, while the expansion of pharma and biotech companies continues to create strong opportunities for software solutions in the region.

Life Science Software Market Coverage

Recent Developments

• In April 2025, Siemens AG acquired Dotmatics, a leading provider of Life Sciences R&D software based in Boston, for USD 5.1 billion from Insight Partners. This acquisition represents a strategic milestone for Siemens, expanding its comprehensive Digital Twin technology and AI-powered software into this rapidly growing complementary market. The acquisition expands Siemens' market-leading position in industrial software by extending the AI-powered Product Lifecycle Management (PLM) portfolio into Life Sciences to seamlessly connect R&D through manufacturing(Source: https://press.siemens.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7604

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344